Molecular Historical Balance Sheet

MOLN Stock

USD 5.29 0.13 2.40%

Trend analysis of Molecular Partners AG balance sheet accounts such as Total Stockholder Equity of 137.3 M provides information on Molecular Partners' total assets, liabilities, and equity, which is the actual value of Molecular Partners to its prevalent stockholders. By breaking down trends over time using Molecular Partners balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Molecular Partners latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Molecular Partners is a good buy for the upcoming year.

Molecular Partners Inventory

(74.15 Million)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Molecular Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Molecular Partners at a specified time, usually calculated after every quarter, six months, or one year. Molecular Partners Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Molecular Partners and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Molecular currently owns. An asset can also be divided into two categories, current and non-current.

Molecular Partners Balance Sheet Chart

At this time, Molecular Partners' Intangible Assets are very stable compared to the past year. As of the 25th of November 2024, Short Term Investments is likely to grow to about 125.6 M, while Total Assets are likely to drop about 193.3 M.

Total Assets Total Current Liabilities Total Stockholder Equity Property Plant And Equipment Net Current Deferred Revenue Common Stock

Total Assets

Total assets refers to the total amount of Molecular Partners assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Molecular Partners books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Molecular Partners balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Molecular Partners AG are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most accounts from Molecular Partners' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	11.6M	15.1M	12.8M	7.8M
Total Assets	172.7M	262.3M	198.4M	193.3M

Other Current Liab Total Assets

Molecular Partners balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.69	-0.04	0.96	0.47	-0.16	-0.26	-0.38	0.15	0.33	0.45	-0.34	0.96	-0.28	0.67	0.54	-0.53	-0.47	-0.3	0.74	-0.36	0.58	1.0	-0.7	0.01	0.72
Other Current Liab	0.69		0.21	0.71	0.78	-0.08	0.39	-0.85	0.51	-0.34	0.8	-0.49	0.57	-0.05	0.95	0.89	-0.83	-0.75	-0.12	0.97	-0.42	0.82	0.66	-0.73	0.57	0.98
Total Current Liabilities	-0.04	0.21		-0.24	0.54	0.95	0.01	-0.43	0.8	-0.02	0.55	-0.51	-0.17	0.39	0.27	0.1	0.11	0.05	0.18	0.24	0.75	-0.01	-0.07	-0.16	0.42	0.16
Total Stockholder Equity	0.96	0.71	-0.24		0.39	-0.38	-0.18	-0.35	0.02	0.24	0.37	-0.26	0.95	-0.35	0.69	0.58	-0.63	-0.51	-0.31	0.74	-0.6	0.6	0.96	-0.7	0.0	0.74
Property Plant And Equipment Net	0.47	0.78	0.54	0.39		0.29	0.38	-0.85	0.62	-0.32	1.0	-0.5	0.41	-0.21	0.81	0.79	-0.54	-0.5	-0.38	0.81	0.03	0.75	0.42	-0.42	0.48	0.81
Current Deferred Revenue	-0.16	-0.08	0.95	-0.38	0.29		-0.21	-0.13	0.63	0.18	0.29	-0.44	-0.26	0.4	0.0	-0.2	0.37	0.32	0.24	-0.04	0.86	-0.3	-0.18	0.0	0.23	-0.13
Net Debt	-0.26	0.39	0.01	-0.18	0.38	-0.21		-0.55	0.17	-0.99	0.4	0.03	-0.36	0.23	0.29	0.61	-0.39	-0.65	0.18	0.27	-0.2	0.57	-0.29	0.18	0.48	0.37
Retained Earnings	-0.38	-0.85	-0.43	-0.35	-0.85	-0.13	-0.55		-0.67	0.48	-0.87	0.32	-0.25	-0.02	-0.87	-0.82	0.75	0.69	0.14	-0.87	0.14	-0.82	-0.34	0.58	-0.65	-0.86
Accounts Payable	0.15	0.51	0.8	0.02	0.62	0.63	0.17	-0.67		-0.16	0.64	-0.38	-0.01	0.38	0.51	0.39	-0.2	-0.28	0.09	0.54	0.4	0.28	0.12	-0.47	0.57	0.44
Cash	0.33	-0.34	-0.02	0.24	-0.32	0.18	-0.99	0.48	-0.16		-0.34	-0.03	0.43	-0.28	-0.25	-0.57	0.31	0.59	-0.23	-0.21	0.18	-0.48	0.35	-0.24	-0.46	-0.31
Non Current Assets Total	0.45	0.8	0.55	0.37	1.0	0.29	0.4	-0.87	0.64	-0.34		-0.53	0.38	-0.18	0.82	0.78	-0.55	-0.5	-0.36	0.81	0.03	0.74	0.41	-0.44	0.54	0.82
Non Currrent Assets Other	-0.34	-0.49	-0.51	-0.26	-0.5	-0.44	0.03	0.32	-0.38	-0.03	-0.53		-0.29	0.01	-0.42	-0.26	0.23	-0.02	-0.11	-0.4	-0.15	-0.06	-0.32	0.44	-0.55	-0.37
Cash And Short Term Investments	0.96	0.57	-0.17	0.95	0.41	-0.26	-0.36	-0.25	-0.01	0.43	0.38	-0.29		-0.52	0.59	0.44	-0.47	-0.3	-0.5	0.64	-0.42	0.5	0.96	-0.64	-0.1	0.63
Net Receivables	-0.28	-0.05	0.39	-0.35	-0.21	0.4	0.23	-0.02	0.38	-0.28	-0.18	0.01	-0.52		-0.14	-0.07	0.2	-0.24	0.9	-0.12	0.39	-0.18	-0.28	0.11	0.17	-0.16
Common Stock Total Equity	0.67	0.95	0.27	0.69	0.81	0.0	0.29	-0.87	0.51	-0.25	0.82	-0.42	0.59	-0.14		0.86	-0.79	-0.65	-0.23	0.98	-0.36	0.79	0.64	-0.73	0.47	0.98
Common Stock Shares Outstanding	0.54	0.89	0.1	0.58	0.79	-0.2	0.61	-0.82	0.39	-0.57	0.78	-0.26	0.44	-0.07	0.86		-0.71	-0.86	-0.17	0.87	-0.4	0.92	0.51	-0.41	0.38	0.93
Non Current Liabilities Total	-0.53	-0.83	0.11	-0.63	-0.54	0.37	-0.39	0.75	-0.2	0.31	-0.55	0.23	-0.47	0.2	-0.79	-0.71		0.67	0.17	-0.82	0.69	-0.77	-0.51	0.68	-0.44	-0.83
Inventory	-0.47	-0.75	0.05	-0.51	-0.5	0.32	-0.65	0.69	-0.28	0.59	-0.5	-0.02	-0.3	-0.24	-0.65	-0.86	0.67		-0.13	-0.71	0.42	-0.88	-0.45	0.31	-0.27	-0.76
Other Current Assets	-0.3	-0.12	0.18	-0.31	-0.38	0.24	0.18	0.14	0.09	-0.23	-0.36	-0.11	-0.5	0.9	-0.23	-0.17	0.17	-0.13		-0.23	0.22	-0.3	-0.28	0.14	0.12	-0.24
Other Stockholder Equity	0.74	0.97	0.24	0.74	0.81	-0.04	0.27	-0.87	0.54	-0.21	0.81	-0.4	0.64	-0.12	0.98	0.87	-0.82	-0.71	-0.23		-0.38	0.83	0.71	-0.77	0.46	0.99
Total Liab	-0.36	-0.42	0.75	-0.6	0.03	0.86	-0.2	0.14	0.4	0.18	0.03	-0.15	-0.42	0.39	-0.36	-0.4	0.69	0.42	0.22	-0.38		-0.43	-0.37	0.34	0.02	-0.44
Property Plant And Equipment Gross	0.58	0.82	-0.01	0.6	0.75	-0.3	0.57	-0.82	0.28	-0.48	0.74	-0.06	0.5	-0.18	0.79	0.92	-0.77	-0.88	-0.3	0.83	-0.43		0.55	-0.41	0.31	0.88
Total Current Assets	1.0	0.66	-0.07	0.96	0.42	-0.18	-0.29	-0.34	0.12	0.35	0.41	-0.32	0.96	-0.28	0.64	0.51	-0.51	-0.45	-0.28	0.71	-0.37	0.55		-0.69	-0.02	0.69
Short Term Debt	-0.7	-0.73	-0.16	-0.7	-0.42	0.0	0.18	0.58	-0.47	-0.24	-0.44	0.44	-0.64	0.11	-0.73	-0.41	0.68	0.31	0.14	-0.77	0.34	-0.41	-0.69		-0.47	-0.68
Intangible Assets	0.01	0.57	0.42	0.0	0.48	0.23	0.48	-0.65	0.57	-0.46	0.54	-0.55	-0.1	0.17	0.47	0.38	-0.44	-0.27	0.12	0.46	0.02	0.31	-0.02	-0.47		0.44
Common Stock	0.72	0.98	0.16	0.74	0.81	-0.13	0.37	-0.86	0.44	-0.31	0.82	-0.37	0.63	-0.16	0.98	0.93	-0.83	-0.76	-0.24	0.99	-0.44	0.88	0.69	-0.68	0.44

Click cells to compare fundamentals

Molecular Partners Account Relationship Matchups

Molecular Partners balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	104.9M	187.5M	172.7M	262.3M	198.4M	193.3M
Other Current Liab	7.0M	9.4M	11.6M	15.1M	12.8M	7.8M
Total Current Liabilities	28.6M	57.7M	46.9M	17.3M	14.4M	13.7M
Total Stockholder Equity	54.1M	107.2M	107.3M	235.2M	176.4M	137.3M
Property Plant And Equipment Net	4.2M	9.4M	8.1M	7.2M	5.7M	4.7M
Current Deferred Revenue	18.3M	42.9M	28.3M	6.4M	4.3M	4.1M
Net Debt	(73.2M)	(126.5M)	(65.8M)	(83.1M)	(63.7M)	(66.8M)
Retained Earnings	(130.9M)	(195.2M)	(251.0M)	(127.8M)	(191.8M)	(182.2M)
Accounts Payable	2.0M	2.8M	4.9M	997K	410K	389.5K
Cash	75.7M	133.7M	71.8M	87.9M	67.3M	94.3M
Non Current Assets Total	5.0M	9.7M	8.5M	7.5M	5.9M	5.0M
Cash And Short Term Investments	95.1M	173.7M	132.8M	249.1M	186.9M	175.8M
Net Receivables	2.5M	159K	25.7M	521K	295K	280.3K
Common Stock Total Equity	2.1M	2.1M	2.2M	2.9M	3.4M	2.3M
Common Stock Shares Outstanding	21.4M	25.0M	31.0M	33.3M	32.8M	26.0M
Liabilities And Stockholders Equity	104.9M	187.5M	172.7M	262.3M	198.4M	193.3M
Non Current Liabilities Total	22.2M	22.7M	18.5M	9.8M	7.5M	7.1M
Inventory	(51.6M)	(486K)	(199K)	(86.7M)	(78.1M)	(74.2M)
Other Current Assets	2.8M	1.3M	5.7M	3.9M	2.5M	2.4M
Other Stockholder Equity	182.8M	299.5M	355.0M	359.3M	364.5M	250.8M
Total Liab	50.8M	80.3M	65.4M	27.1M	21.9M	40.7M
Property Plant And Equipment Gross	4.2M	9.4M	20.9M	21.9M	22.0M	23.1M
Total Current Assets	99.9M	177.8M	164.2M	254.8M	192.5M	188.3M
Intangible Assets	772K	347K	330K	271K	212K	245.5K
Common Stock	2.2M	2.9M	3.2M	3.6M	3.6M	2.7M
Short Term Investments	19.4M	40M	61M	161.2M	119.6M	125.6M
Other Liab	20.9M	16.6M	13.7M	6.2M	5.6M	5.3M
Net Tangible Assets	53.4M	106.9M	107.0M	234.9M	270.1M	283.6M
Net Invested Capital	54.1M	107.2M	107.3M	235.2M	176.4M	139.6M
Net Working Capital	71.3M	120.1M	117.3M	237.5M	178.0M	152.3M
Property Plant Equipment	4.2M	9.4M	8.1M	7.2M	8.3M	5.9M
Capital Stock	2.2M	2.9M	3.2M	3.6M	3.6M	3.2M

Pair Trading with Molecular Partners

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.

Moving against Molecular Stock

0.4	A	Agilent Technologies Earnings Call Today	Pair Corr
0.31	ME	23Andme Holding	Pair Corr

The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.

The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:

How To Invest In Molecular

Details

Is Molecular Stock a good investment?

Details

What is Molecular Partners' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.13)

Revenue Per Share

0.182

Quarterly Revenue Growth

(0.73)

Return On Assets

(0.21)

Return On Equity

(0.37)

The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Molecular Historical Balance Sheet

Molecular Partners Inventory

(74.15 Million)

About Molecular Balance Sheet Analysis

Molecular Partners Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Property Plant And Equipment Net

Current Deferred Revenue

Molecular Partners balance sheet Correlations

Molecular Partners Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Molecular Partners balance sheet Accounts

Pair Trading with Molecular Partners

Moving against Molecular Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 0.99	Other Stockholder Equity
Common Stock	+ 0.98	Other Current Liab
Other Stockholder Equity	+ 0.98	Common Stock Total Equity
Common Stock	+ 0.98	Common Stock Total Equity

Cash	- 0.99	Net Debt
Property Plant And Equipment Gross	- 0.88	Inventory
Other Stockholder Equity	- 0.87	Retained Earnings
Common Stock Total Equity	- 0.87	Retained Earnings
Non Current Assets Total	- 0.87	Retained Earnings
Inventory	- 0.86	Common Stock Shares Outstanding